Popular Elsewhere
A look at the stories ranking highly on various news sites.
The Huffington Post's most read article says while Wednesday's bomb blast in Mumbai "made for grim reading", it created a striking example of the "co-operative spirit that social networks can help to build". Dubbed as the world's most moving spreadsheet - shared on Google docs and advertised on Twitter - . "One user @jacbobrohan in Bandra West, offered a place to stay, while @MithunK offered the use of his office phone for those who needed to contact loved ones. A user in the Andheri East section of the city (@gsurya) logged in to offer his type A2-negative blood. Others did the same" said the Huffington Post.
The New York Times' Maureen Dowd's widely e-mailed article asks . Apparently there is - and it is about dogs. She says a new book reveals that Hitler supported a German school that tried to teach mastiffs to talk to humans. To be more specific, the claim is that dogs were trained to answer "Mein Fuhrer" to the question "who is your leader". Cue the "barking mad" headlines.
New research could completely , a big hitting Radio Netherlands Worldwide article says. Researcher Feiko Rijken says the prevailing theory - when skin is exposed to the sun enzymes in the skin are released causing it to crease - is wrong. Instead he says the wrinkles are caused by cells combating infection. RNW points out that this could have a big impact given the huge amounts of money being made in the skin cream business.
A popular New Scientist article says lizards have worked out how to unplug holes to reach food. Why does it matter? Well it means that . But, it points out, other tests have shown lizards are still less intelligent than crows and primates.
A popular Al Jazeera article promises to reveal . It claims that in 2008 antipsychotics became the single top-selling therapeutic class of prescription drugs. The article is particularly concerned with a seeming expansion in prescription to the very young and very old. It imagines a very cynical view is taken by drug companies. "The decision to continue pushing the drug despite side effects is matter of cost benefit analysis: Whether you will make more money by continuing to market the drug for off-label use, and perhaps defending against lawsuits, than you would otherwise."
The 
